SWOG clinical trial number
CTSU/NRG-GI002

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Closed
Phase
Abbreviated Title
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Activated
10/12/2016
Closed
02/22/2021
Participants
CTSU, ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Gastrointestinal Cancer

Eligibility Criteria Expand/Collapse

Please see eligibility criteria in protocol on www.CTSU.org

Publication Information Expand/Collapse

2021

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial

O Rahma;G Yothers;T Hong;M Russell;Y You;W Parker;S Jacobs;L Colangelo;P Lucas;M Gollub;W Hall;L Kachnic;N Vijayvergia;M O'Rourke;B Faller;R Valicenti;T Schefter;K Moxley;R Kainthla;P Stella;E Sigurdson;N Wolmark JAMA Oncology, Aug 1;7(8):1225-1230

PMid: PMID34196693 | PMC number: PMC8251652

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
85%
Open
Phase